(2)No such file or directory: exec failed (ads.cgi)

Bookmark This Page  ||   Make This My Homepage  ||   Link To Us  ||   Tell a Friend  ||   Search
 

Home

UK Projects

International Projects

Contractor News

Industry Moves

Contractors'
Guides

Contractors'
Profiles

Technical Toolbox

Glossary

Technip Awarded Contract for Vaccine Plant in China

Technip LogoTechnip has been awarded a contract by the Chengdu Institute of Biological Products (CDIBP) for the design, construction and qualification of a new production unit for Japanese encephalitis vaccines. This unit will be located in the Sichuan province of China, and will have an initial production capacity of 100 million doses per year.

The project represents a total investment of several million dollars, and is partially financed by PATH (1), an international non-profit organization, through its Japanese Encephalitis Project, which is supported by the Bill & Melinda Gates Foundation. The objective is to give CDIBP, with support from PATH, the ability to furnish World Health Organization (WHO) quality vaccines to disadvantaged populations in the Asia Pacific region.

For this contract, Technip will carry out the design and front-end engineering, project management, procurement, construction and qualification of the installations according to World Health Organization (WHO) regulations.

Technip's operations and engineering centre in Paris will provide the pharmaceutical and regulatory expertise in support of Technip's Shanghai center, which will carry out the studies, project management and execution.

This new project should come on stream for production in the second half of 2008.

(1) PATH works with private- and public-sector partners to create sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health.

Find out more about  Technip

Search for more Technip News

Posted 05/07/06

Back


Get Listed  ||   Advertising Opportunity  ||   About Us  ||   Contact Us  ||   Legal

© Copyright 2006. All rights reserved.